who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Bristol Myers Squibb (BMY) earnings date & Q3 2026 results

US GAAP · quarter ended 09/30/2026 · released Oct 29

Net Earnings/(Loss) Attributable to BMS

$2,162M

down 1.8% y/y

Total Revenues

$13,069M

up 6.9% y/y

Next report

~ Feb 4

not announced yet

The quarter in brief

GAAP net income attributable to BMS was $2,162 million, or $1.05 diluted per share, versus $2,201 million, or $1.08, a year earlier.

Key growth driver: Net product sales — the fastest-growing revenue line: $12,606, +6% y/y. · by the Q3 2026 report

All figures in $M.

Sankey diagram of BMY (Bristol Myers Squibb) earnings report for Q3 2026: revenue, costs and profitNet product sales$12,606 · +6.4%Alliance and otherrevenues$463 · +24.5%Total Revenues$13,069 · +6.9%Cost of productssold$4,146 · +20.7%Selling, generalandadministrative$1,699 · −5.0%Research anddevelopment$2,365 · −6.4%Acquired IPRD$1,558 · +146%Amortization ofacquiredintangible assets$458 · −44.9%Other(income)/expense,net$307 · vs −$108Earnings/(Loss)Before IncomeTaxes$2,536 · −18.6%19.4% marginIncome tax provision$374 · −59.3%14.7% effective rateNet Earnings/(Loss)Attributable to BMS$2,162 · −1.8%$1.05/sh · 16.5% margin
Sankey diagram of BMY (Bristol Myers Squibb) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Net product sales$12,606 · +6.4%
Alliance and other revenues$463 · +24.5%
Total Revenues$13,069 · +6.9%
Cost of products sold$4,146 · +20.7%
Selling, general and administrative$1,699 · −5.0%
Research and development$2,365 · −6.4%
Acquired IPRD$1,558 · +146%
Amortization of acquired intangible assets$458 · −44.9%
Other (income)/expense, net$307 · vs −$108
Earnings/(Loss) Before Income Taxes$2,536 · −18.6% · 19.4% margin
Income tax provision$374 · −59.3% · 14.7% effective rate
Net Earnings/(Loss) Attributable to BMS$2,162 · −1.8% · $1.05/sh · 16.5% margin

Verdict: GAAP net income attributable to BMS was $2,162 million, or $1.05 diluted per share, versus $2,201 million, or $1.08, a year earlier.

Total revenues were $13,069 million versus $12,222 million, and GAAP earnings before income taxes were $2,536 million versus $3,114 million a year ago.

Source and notation

Source: Bristol Myers Squibb earnings release, 8-K EX-99 of 10/29/2026 (SEC EDGAR).

Open as an image: Bristol Myers Squibb (BMY), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Bristol Myers Squibb (BMY) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/bmy. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/bmy"><img src="https://whoreportstoday.com/t/bmy/img/bristol-myers-squibb-bmy-earnings-sankey.png" alt="Bristol Myers Squibb (BMY) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/bmy">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/bmy/img/bristol-myers-squibb-bmy-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/bmy">Bristol Myers Squibb (BMY) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Bristol Myers Squibb — Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. · Text: Wikipedia, CC BY-SA 4.0, abridged

The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. Market share (US pharma & biotech): ≈7% by TTM revenue.

Company reports

Q3 2026latest breakdownGAAP net income attributable to BMS was $2,162 million, or $1.05 diluted per share, versus $2,201 million, or $1.08, a…
Q2 2026A strong quarter — Growth Portfolio (+15%) and a swing to net Other Income offset Legacy Portfolio erosion and higher…

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026revenue $49.75–50.25B (raised)EPS (non-GAAP) $6.35–6.55 (raised)revenue $48.2BEPS (GAAP) $3.46revenue +3…4%

Same quarter a year ago (ended December 31, 2025): revenue $12.5B, EPS (GAAP) $0.54

How we calculate

Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +4%).

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Oct 29, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

BMY earnings history: past report dates

Oct 29, 2026 Thu7:05 ambefore market openSep 30, 2026$13.1B+7% y/y$1.05−3% y/y
Jul 30, 2026 Thu7:05 ambefore market openJun 30, 2026$13.0B+6% y/y$1.62+153% y/y
Apr 30, 2026 Thu7:01 ambefore market openMar 31, 2026$11.5B+3% y/y$1.31+9% y/y
Feb 5, 2026 Thu7:07 ambefore market openDec 31, 2025≈$12.5B+1% y/y≈$0.54+980% y/y
Oct 30, 2025 Thu7:09 ambefore market openSep 30, 2025$12.2B+3% y/y$1.08+80% y/y
Jul 31, 2025 Thu7:06 ambefore market openJun 30, 2025$12.3B+1% y/y$0.64−23% y/y
Apr 24, 2025 Thu7:11 ambefore market openMar 31, 2025$11.2B−6% y/y$1.20
Feb 6, 2025 Thu7:46 ambefore market openDec 31, 2024≈$12.3B+8% y/y≈$0.05−94% y/y
Oct 31, 2024 Thu7:52 ambefore market openSep 30, 2024$11.9B+8% y/y$0.60−35% y/y
Jul 26, 2024 Fri7:46 ambefore market openJun 30, 2024$12.2B+9% y/y$0.83−16% y/y
Apr 25, 2024 Thu7:47 ambefore market openMar 31, 2024$11.9B+5% y/y−$5.89
Feb 2, 2024 Fri7:46 ambefore market openDec 31, 2023≈$11.5B+1% y/y≈$0.87−8% y/y
Oct 26, 2023 Thu7:44 ambefore market openSep 30, 2023$11.0B−2% y/y$0.93+24% y/y
Jul 27, 2023 Thu7:50 ambefore market openJun 30, 2023$11.2B−6% y/y$0.99+50% y/y
Apr 27, 2023 Thu7:45 ambefore market openMar 31, 2023$11.3B−3% y/y$1.07+81% y/y
Feb 2, 2023 Thu8:43 ambefore market openDec 31, 2022≈$11.4B−5% y/y≈$0.95−11% y/y
Show all 16 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Bristol Myers Squibb: 15-year financials

202548,1947,05412,8455,045
202448,300−8,94813,9424,863
202345,0068,02512,6514,744
202246,1596,32711,9484,634
202146,3856,99415,2344,396
202042,518−9,01513,2994,075
201926,1453,4397,3742,679
201822,5614,9206,1152,613
201720,7761,0074,2202,577
201619,4274,4571,8432,547
201516,5601,5651,2852,477
201415,8792,0042,6222,398
201316,3852,5633,0082,309
201217,6211,9606,3932,286
201121,2443,7094,4732,254

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Bristol Myers Squibb: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
202590,03818,47347,08810,20929,39023,417
202492,60316,33551,47710,34629,78023,774
202395,15929,43042,64511,46431,77022,262
202296,82031,06143,2179,12327,27321,890
2021109,31435,94649,31713,97933,26221,868
2020118,48137,82252,67614,54630,19219,080
2019129,94451,59849,49612,34629,35418,304
201834,98614,0318,5986,91117,71610,654
201733,55111,7417,9625,42114,8549,563
201633,70716,1776,5744,23713,7048,841
201531,74814,2666,8282,38510,4158,017
201433,74914,8528,4225,57114,6088,461
201338,59215,1548,3403,58618,91612,440
201235,89713,6238,0581,6569,5218,279
201132,97015,9565,4915,77615,3187,780

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated8,67812,182−3,504
· incl. D&A (non-cash add-back)depreciation & amortization1,8143,034
· incl. stock-based comp (non-cash)share-based compensation419420
Capexpurchases of property & equipment−996−941−55
Free cash flow ≈operating cash flow − capex7,68211,241−3,559
Investing activities, netcapex, acquisitions, securities−3,849−2,674−1,175
· incl. acquisitionsbusinesses net of cash acquired−1,268−2,237+969
Financing activities, netdebt, buybacks, dividends−5,412−4,319−1,093
· incl. dividends paid−3,857−3,783−74
FX effect on cash−61190−251
Net change in cash−6445,379−6,023
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: $23.4B (26% of total assets). Compare with other S&P 500 companies →

Corporate governance

1.5/2mostly good

  • Feb 202610-K FY2025: in September 2025 the parties reached a settlement of the Celgene shareholder class action (purchasers from Apr 2017 to Apr 2018); the court granted preliminary approval in Dec 2025. sec.gov ↗
  • May 2026The court granted final approval to a $239M settlement of the suit by former Celgene shareholders over overstated prospects for Otezla and Zeposia. news.bloomberglaw.com ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Feb 2026Dividend per share $1.84 (2020) → $2.49 (2025), raised every year; diluted shares −9.7% over 5 years. data.sec.gov ↗

Scoring: 2.0 −0.5 (criterion 9: $239M settlement of the former Celgene shareholders' suit, approved by the court in May 2026) = 1.5

Share classes
Single class of common stock; the Celgene CVR is a separate non-voting security.
Dilution
Diluted shares 2,258M (2020) → 2,039M (2025), −9.7%; SBC 1.1% of revenue; the all-stock Celgene acquisition was in 2019, outside the 5-year window.
Disclosure
Full reporting.
Dividends
Dividend raised every year: $1.84 (2020) → $2.49 (2025); buybacks of $5–8B in 2021–2023.
Lawsuits & regulators
Celgene suit (2018) settled for $239M, approved May 2026 → −0.5; CVR holders' suits unresolved → no deduction; the 2004 SEC case and the 2002–2004 shareholder suit are older than 15 years and not counted.
Related parties
Related-party transactions limited to routine BlackRock/Vanguard/JPM services on market terms (2026 proxy).

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Bristol Myers Squibb (BMY) earnings: FAQ

When is BMY's next earnings date?

We have not yet seen an announcement of the date from Bristol Myers Squibb (BMY). Based on last year's report on Feb 5, 2026, the next report is expected around Feb 4, 2027.

What time does BMY report earnings?

Bristol Myers Squibb usually reports before market open: its latest results release was filed with the SEC at 7:05 am ET on Oct 29, 2026.

When did BMY last report earnings?

Bristol Myers Squibb reported Q3 2026 results on Oct 29, 2026.

What has Bristol Myers Squibb guided for FY2026?

Company guidance for FY2026: revenue $49.75–50.25B (raised); EPS (non-GAAP) $6.35–6.55 (raised). A year ago (FY2025): revenue $48.2B, EPS (GAAP) $3.46. Implied growth: revenue +3…4%. Source: the company's earnings release (Form 8-K filed Oct 29, 2026).

Where can I find Bristol Myers Squibb's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to BMY's filings; this page breaks the latest report down in a Sankey chart.

What was BMY's net income in Q3 2026?

Bristol Myers Squibb reported net income of $2,162M for Q3 2026 (−1.8% year over year), under US GAAP.

Does Bristol Myers Squibb pay dividends?

Yes. In 2025, Bristol Myers Squibb paid $5,045M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Bristol Myers Squibb's revenue changed since 2011?

Per its 10-K filings, revenue grew 2.3x: $21,244M in 2011 and $48,194M in 2025. The peak was $48,300M in 2024. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q4 FY2026 · CRL · Q3 2026 · CVS · Q3 2026 · DGX · Q3 2026 · DHR · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy